8-K: Viking Therapeutics Advances Obesity Pipeline, Reports Q4/FY25 Results

Viking Therapeutics announced its Q4 and full-year 2025 financial results, alongside significant progress in its obesity drug pipeline, including plans for Phase 3 trials for oral VK2735 and ongoing subcutaneous VK2735 studies.

Summary

• Net loss for the fourth quarter of 2025 was $157.7 million, or $1.38 per share, compared to $35.4 million, or $0.32 per share, for the same period in 2024.
• Net loss for the full year 2025 was $358.5 million, or $3.19 per share, compared to $110.0 million, or $1.01 per share, for the full year 2024.
• Research and development expenses increased significantly to $153.5 million in Q4 2025 from $31.0 million in Q4 2024, and to $345.0 million for FY 2025 from $101.6 million in FY 2024.
• Cash, cash equivalents, and short-term investments totaled $706 million as of December 31, 2025, down from $903 million as of December 31, 2024.
• Enrollment for the Phase 3 VANQUISH-1 study for subcutaneous VK2735 in obesity was completed ahead of schedule, exceeding the target of 4,500 patients.
• Enrollment for the Phase 3 VANQUISH-2 study for subcutaneous VK2735 in obesity and type 2 diabetes is nearing completion and is expected to be finalized in 1Q26.
• Oral VK2735 is planned to advance into Phase 3 development for obesity in 3Q26, following positive Phase 2 VENTURE-Oral Dosing study results showing up to 12.2% weight reduction in 13 weeks.
• A Phase 1 maintenance dosing study for VK2735, evaluating monthly subcutaneous and various oral dosing regimens, is fully enrolled with data expected in 3Q26.
• An Investigational New Drug (IND) application for a novel amylin agonist is planned for filing in 1Q26, expanding the company's obesity franchise.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive update, driven by strong clinical progress and pipeline expansion, despite increased R&D expenses typical for a company advancing multiple late-stage assets. The significant cash burn is offset by substantial cash reserves and promising trial momentum.

Positives

• Rapid progress across the obesity portfolio, including significant advancements in the VK2735 clinical program.
• VANQUISH-1 enrollment completed ahead of schedule, exceeding the target of over 4,500 patients, demonstrating strong interest.
• VANQUISH-2 enrollment is nearing full completion, expected in 1Q26, maintaining momentum in the Phase 3 program.
• Positive top-line results from the Phase 2 VENTURE-Oral dosing trial for VK2735, showing statistically significant weight reductions of up to 12.2% in 13 weeks.
• Oral VK2735 is advancing to Phase 3 development in 3Q26, offering a differentiated oral formulation alongside the injectable.
• The VK2735 maintenance dosing study is fully enrolled, with data expected in 3Q26, exploring flexible long-term treatment options.
• Planned IND filing for a novel amylin agonist in 1Q26, diversifying the obesity pipeline.
• Strong quarter-end cash position of $706 million, providing resources for ongoing development.
• Entered into a comprehensive manufacturing and supply agreement for VK2735, building commercial foundation.
• VK2735 demonstrated encouraging safety and tolerability profiles in both subcutaneous and oral formulations, with mostly mild or moderate GI-related adverse events.
• Improvements in metabolic syndrome and prediabetic status were observed with VK2735 in the VENTURE study.

Negatives

• Net loss significantly increased to $157.7 million in Q4 2025 from $35.4 million in Q4 2024.
• Full-year 2025 net loss rose to $358.5 million from $110.0 million in FY 2024.
• Research and development expenses surged to $153.5 million in Q4 2025 and $345.0 million for FY 2025, reflecting high investment burn.
• Cash, cash equivalents, and short-term investments decreased by $197 million year-over-year, from $903 million to $706 million.

Risks

• Risks associated with the success, cost, and timing of product candidate development activities and clinical trials for VK2735, VK0214, VK2809, and other incretin and receptor agonists.
• Risks that prior clinical and preclinical results may not be replicated in future studies.
• Risks regarding regulatory requirements and the ability to obtain necessary approvals.
• Other risks described in the company's most recent periodic reports filed with the SEC, including the Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q.

Future Outlook

The company expects 2026 to be another exciting and productive year, with plans to advance oral VK2735 into Phase 3 development in 3Q26, report data from the maintenance dosing study in 3Q26, and file an IND for its novel amylin agonist in 1Q26. They also anticipate completing enrollment in the VANQUISH-2 study in 1Q26.

Management Comments

• "The past year was an exceptional year for Viking marked by rapid progress across our obesity portfolio."
• "We expect 2026 to be another exciting and productive year and look forward to providing updates along the way."
• "The company believes the rapid pace of enrollment observed in the VANQUISH program demonstrates the significant continued enthusiasm among investigators, clinicians and patients for the VK2735 program."
• "The company believes the availability of both an oral and an injectable formulation is an important factor differentiating VK2735 from competitive agents, as no other dual or triple agonist is currently available in both formulations."
• "Providing flexible dosing options for long-term therapy may improve treatment persistence following achievement of individual weight loss goals."

Industry Context

StockSavvy.ai notes that the obesity drug market is highly competitive and rapidly expanding, with significant demand for effective and convenient weight loss solutions. Viking's dual GLP-1/GIP agonist, VK2735, positions it directly against established players like Novo Nordisk (Wegovy/Ozempic) and Eli Lilly (Zepbound/Mounjaro), which also target GLP-1 and GIP receptors. The development of both subcutaneous and oral formulations for the same active ingredient, VK2735, could offer a significant competitive advantage by providing patient flexibility and potentially reducing side effects associated with switching therapies, addressing a key unmet need in long-term weight management. The planned IND for an amylin agonist further diversifies its pipeline in the metabolic disorder space.

Comparison to Industry Standards

• VK2735's reported weight loss of up to 14.7% (subcutaneous) and 12.2% (oral) in 13 weeks is competitive with early-stage data or initial phases of leading GLP-1/GIP agonists. For instance, Eli Lilly's Zepbound (tirzepatide) showed average weight reductions of 15-20% over 72 weeks in its SURMOUNT trials, and Novo Nordisk's Wegovy (semaglutide) showed around 15% weight loss over 68 weeks. Viking's 13-week data is promising for a relatively short treatment window, suggesting a rapid onset of action comparable to the initial phases of these market leaders.
• The rapid enrollment in the VANQUISH Phase 3 trials, with VANQUISH-1 exceeding its 4,500-patient target ahead of schedule, indicates strong investigator and patient interest, mirroring the high demand seen for other effective obesity treatments in clinical development and on the market, such as those from Eli Lilly and Novo Nordisk.
• The strategy of developing both oral and injectable formulations of the same active molecule (VK2735) is a potential differentiator, as current market leaders typically offer one or the other, or different molecules for different delivery methods. This approach could offer a unique patient experience for long-term weight management and adherence, potentially setting a new standard for flexibility.

Stakeholder Impact

• Shareholders face increased short-term losses due to high R&D investment but stand to benefit from potential significant long-term value creation if VK2735 successfully navigates Phase 3 and gains regulatory approval.
• Patients are offered promising new treatment options for obesity and metabolic disorders, including flexible dosing and both oral and injectable formulations of VK2735.
• Employees can expect stable to growing employment opportunities due to continued investment in R&D and the building of commercial infrastructure.
• Regulatory authorities are actively engaged, with ongoing discussions and planned filings for advanced clinical programs.

Next Steps

• Complete enrollment in the VANQUISH-2 study (expected 1Q26).
• File an Investigational New Drug (IND) application for the novel amylin agonist (planned 1Q26).
• Advance oral VK2735 into Phase 3 development for obesity (expected 3Q26).
• Report results of the VK2735 maintenance dosing study (expected 3Q26).
• Participate in the Leerink Partners 2026 Global Healthcare Conference (March 8-11, 2026).
• Participate in the 2026 Jefferies Biotech on the Beach Summit (March 10-11, 2026).
• Participate in the Raymond James Biotech/BioPharma Conference (April 14, 2026).

Key Dates

Recommendation

While the clinical progress for VK2735 is highly encouraging and positions Viking as a strong contender in the lucrative obesity market, the significant increase in R&D expenses and net losses, coupled with a reduction in cash reserves, warrants a 'Hold' recommendation. The company is executing well on its pipeline, but the financial burn rate is substantial. Investors should monitor the upcoming Phase 3 data and IND filing, as well as the cash runway, before making further investment decisions. The stock has likely already priced in much of the positive clinical momentum.

Keywords

Viking Therapeutics, VKTX, Obesity, GLP-1, GIP, Dual Agonist, VK2735, Phase 3, Clinical Trials, Biopharmaceutical, Metabolic Disorders, Weight Loss, Amylin Agonist, Financial Results, Biotech, Drug Development, FDA, VANQUISH, VENTURE